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SUMMARY
We report a case of CD8+/Vb5.1+ T-cell large granular lymphocyte leukemia (T-LGL leukemia)
presenting with mild lymphocytosis, severe autoimmune neutropenia, thrombocytopenia, polyarthritis and
recurrent infections with a chronic disease course. Immunophenotyping showed an expansion of CD3+/
TCRab+/CD8+bright/CD11c+/CD57x/CD56x large granular lymphocytes with expression of the TCR-
Vb5.1 family. Southern blot analysis revealed a clonal rearrangement of the TCR b-chain gene.
Hematopoietic growth factors, high dose intravenous immunoglobulin and corticosteroids were of limited
therapeutic benefit to correct the cytopenias. During the disease course, the patient developed a severe
cutaneous leg ulcer and bilateral vascular mammary skin lesions. Treatment with 2-deoxycoformycin
resulted in both clinical and hematological complete responses, including the resolution of vascular skin
lesions. Combined immuno-staining with relevant T-cell associated and anti-TCR-Vb monoclonal
antibodies proved to be a sensitive method to assess the therapeutic effect of 2-deoxycoformicin and to
evaluate the residual disease. Copyright # 2002 John Wiley & Sons, Ltd.
key words: rheumatoid arthritis; large granular lymphocytes; CD8+; skin lesions; autoimmune
cytopenias; 2-deoxycoformycin
INTRODUCTION
Lymphoproliferative disorders of large granular lymphocytes (LGL) comprise a large spectrum
of polyclonal, oligoclonal or monoclonal expansions of LGL the latter being designated LGL-
leukemia.1,2 The majority of cases are of T-cell origin, mainly with a CD3+/TCRab+/
CD8+bright immunophenotype, and a minority derived from NK-cells. Arthritis and cytopenias
are common findings. Cytopenias, often neutropenia and anemia may be autoimmune in nature
or result from a T cell-mediated suppressor effect on the hematopoiesis; thrombocytopenia
occurs less frequently. Splenomegaly and hepatomegaly are relatively frequent while
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lymphadenopathy and skin involvement are extremely rare (E. Granjo et al., unpublished
data).1-3
Several agents, including corticosteroids, hematopoietic growth factors, high dose
intravenous immunoglobulins, low dose methotrexate, cyclosporin A and cyclophosphamide
have been used with variable success in the treatment of LGL-leukemia and associated
conditions.4–9 Recently, purine analogues such as fludarabine, 2-chlorodeoxyadenosine and
2-deoxycoformycin (2-DCF), have also been proved to have potent activity in the treatment of
chronic T-cell leukemias, including a few cases of LGL-leukemia.10–12
We describe a patient with a CD3+/TCRab+/CD8+bright/Vb5.1+ LGL leukemia, who
presented with arthritis, mild lymphocytosis, autoimmune cytopenias (neutropenia and
thrombocytopenia), recurrent infections and vascular mammary skin lesions that were
successfully treated with 2-DCF.
CASE REPORT
A 71-year-old female was referred to the Department of Hematology (Hospital S. Joa˜o, Porto,
Portugal) in October 1991 for investigation of lymphocytosis, severe neutropenia and
thrombocytopenia detected in a routine blood analysis. She had a previous history for 5 years
of arthralgias and synovitis of the wrists and the second and third metacarpo-phalangeal joints.
Hepatosplenomegaly and lymphadenopathy were not present. The main clinical and laboratory
features at presentation and during the disease course are shown in Table 1. Peripheral blood
counts at diagnosis were: white blood cells (WBC) 7.2r109/l, neutrophils 0.5r109/l,
lymphocytes 6.3r109/l, platelets (PLT) 88r109/l and hemoglobin (HGB) 12.3 g/dl. The
majority of circulating lymphocytes were LGL and flow cytometry analysis showed a CD3+/
TCRab+/CD8+bright/CD4x phenotype in 90% of cells. The expanded CD8+ LGL population
expressed CD11c, was negative for NK-associated markers (CD11c+, CD16x, CD56x,
CD57x) and, unlike normal circulating CD3+/TCRab+/CD8+bright LGL, were CD5 negative.
Like normal CD8+ LGL, the cells expressed activation-markers (CD11a+bright/CD25x/
CD122+/HLA-Dr+). Neutrophil-associated and platelet-associated IgG antibodies were
detected by flow cytometry, whereas the direct anti-human immunoglobulin Coomb’s test
was negative. There was a polyclonal hypergammaglobulinemia (IgA 1043 mg/dl, with a normal
range of 90 to 450 mg/dl and IgG 1955 mg/dl with normal range of 80 to 1800 mg/dl). Serum
rheumatoid factor was positive and X-ray of the joints showed soft tissue swelling, bone
erosions of the hand small joints and narrowing of the joint spaces. HLA studies showed A2,24;
B6,2; Cw2,3; DR4,6; DQw1,3. There was no serological evidence for recent or persistent
infection by cytomegalovirus, Herpes simplex, Herpes zoster, Epstein-Barr, human hepatitis B
and C, human immunodeficiency type I and II or human T-cell lymphotropic type 1 and 2
viruses. The bone marrow (BM) aspirate showed infiltration (25%) by LGL and the BM
trephine biopsy revealed an interstitial lymphocytic infiltrate and increased numbers of plasma
cells. Cytogenetic studies in the BM cells revealed a normal karyotype. TCR-beta chain variable
region (TCR-Vb) repertoire analysis using a panel of antibodies against the variable domains of
the TCR beta chain (Immunotech, Marseille, France) showed that 92% of the blood CD8+
T-cells expressed the TCR-Vb5.1 family, as compared to a value of 3.0t1.2% (meantstandard
deviation) in normal peripheral blood CD8+ T-cells. Southern blotting using specific probes for
the TCR-beta gene region (Cb, TCRBC and TCRBJ2) and ECO RI and HIND III restriction
enzymes showed a rearranged pattern of the TCR-beta chain gene compatible with a clonal
T-cell expansion.
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The clinical course was stable for 1 year, when there was a decrease in the neutrophil count
concomitantly to recurrent respiratory infections. From 1992 to 1995 she received high dose
intravenous immunoglobulin (IVIg), prednisone and granulocyte-colony stimulating factor
(G-CSF) with only minor transient benefit. In December 1994, she manifested with a severe
cutaneous leg ulcer that required treatment with broad-spectrum antibiotics and G-CSF. At
that time she also developed B symptoms, hepatosplenomegaly and bilateral vascular mammary
skin lesions (Figure 1A). Mammary skin biopsy showed capillary ectasies in the dermis and a
perivascular infiltrate by T-lymphocytes (Figure 1B). Because of the low benefit obtained with
corticosteroids, G-CSF and IVIg and persistence of lymphocytosis and cytopenias, she was
started on 2-DCF 7 mg i.v., twice a month for 10 courses (March 95 to November 95). During
this period she was hospitalized for pneumonia and developed a transient pancytopenia
reaching minimum values of WBC of 0.8r109/l, HGB of 7.4 g/dl, PLT of 39r109/l and a
lymphopenia with both low CD4+ (0.143r109/l) and CD8+ (0.345r109/l) lymphocyte counts.
Clinical and hematological re-evaluation after 10 courses of 2-DCF showed a complete
resolution of the cutaneous lesions and hepatosplenomegaly, a rise in the neutrophil and PLT
counts and the anti-platelet and anti-neutrophil autoantibodies were no longer detected. By this
time the WBC count was 3.2r109/l with 56% neutrophils and 28% lymphocytes, the PLT count
was 104r109/l and HGB was 13.1 g/dl. The patient remained lymphopenic for 1 year and
developed a severe perianal herpetic infection that was successfully treated with acyclovir. The
blood counts continued to recover progressively until reaching normal values. In December
1997, 2 years after treatment, she had: WBC of 5.0r109/l (neutrophils 61%, lymphocytes 25%),
PLT 144r109/l and HGB 13.9 g/dl. Combined four-colour staining with anti-CD8, anti-CD5,
anti-CD28 and TCR-Vb5.1 MAb revealed that the abnormal CD8+/Vb5.1+/CD5x/CD11c+/
CD57x LGL clone had decreased markedly, representing 53% of the CD8+ circulating
lymphocytes. Additional flow cytometric studies detected a new CD8+/Vb17.1+ LGL
expansion, with different immunophenotypic properties, representing 15% of CD8+
lymphocytes (normal value 4.7t2.4%). In contrast to CD8+/Vb5.1+ leukemic LGL, CD8+/
Vb17.1+ LGL were CD5+dim/CD11cx/CD57+; other immunophenotypic findings were
similar. A BM aspirate showed 12% lymphocytes, 53% of which were CD8+ LGL. At the
last reassessment carried out in November 2000 blood counts were normal and the abnormal
CD8+/Vb5.1+ LGL clone was reduced to minimal residual levels (9% of blood CD8+ T-cells)
whereas CD8+/Vb17.1+ LGL remained stable (17% of CD8+ T-cells). Although the abnormal
CD8+/Vb5.1+ LGL clone was still clearly detected by flow cytometry, Southern blot-based
molecular biology studies revealed a germ-line pattern of the TCR-b chain gene.
DISCUSSION
We described a case of a CD8+ LGL leukemia associated with autoimmune cytopenias,
arthritis and recurrent infections and who developed vascular mammary skin lesions during the
disease course. The patient achieved a complete clinical and hematological response with
2-DCF including resolution of the vascular breast lesions.
Unusual features in our patient were the vascular mammary skin lesions and the therapeutic
effect obtained with 2-DCF while other manifestations were those typically found in LGL
leukemia.
Although association of LGL lymphoproliferative disorders with cytopenias and arthritis is
well established, reports on the association of LGL-leukemia and cutaneous lesions are scarce
(E. Granjo et al., unpublished data).3 To the best of our knowledge to date only one case of
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Figure 1. Bilateral mammary skin lesions (A) whose biopsy revealed vascular ectasies and a
perivascular lymphocytic infiltrate (B)
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CD8+ LGL with cutaneous infiltration has been described3 and we have recently seen a case
with a CD4+/CD8+dim/CD56+ LGL leukemia and skin lesions, the latter diagnosed as
disseminated granuloma annulare.20 Although in our patient skin histology revealed a vascular
proliferation suggestive of a reactive condition, the presence of a lymphoid infiltrate with a
T-cell phenotype and the response to 2-DCF would suggest that the cutaneous lesions were
associated with the LGL-leukemia. It has been shown that LGL exhibit cytotoxic activity
against endothelial cells in certain experimental conditions13,14 and may also induce vascular
proliferation and endothelial damage by means of secreting a variety of cytokines and growth
factors, such as tumour necrosis factor alpha (TNF-alpha) and gamma interferon (IFN-
gamma), that interfere with endothelial proliferation and adhesion15–17 and may be responsible
for vascular damage.18,19 In line with these observations, it could be speculated that the
vascular mammary skin lesions were the result of direct or indirect damage of the endothelial
cells by the expanded LGL population.
The response to 2-DCF in our patient was remarkable on the organomegaly, skin lesions and
cytopenias as well as on lymphocytosis with the almost complete disappearance of the
circulating leukemic LGL clone. 2-DCF was well tolerated except for an increased risk of
infections by opportunistic organisms. Therefore, 2-DCF should be used only if LGL-
leukemias have frank progression and anti-viral and anti-fungal prophylaxis should always be
considered. There have been a few other cases of T-LGL leukemia achieving a long-term
clinical and hematological remission with 2-DCF, without evidence of relapse up to 4 years
after finishing therapy.11,12 Similar responses were previously reported with cyclospho-
sphamide8,9 whereas treatment with cyclosporin A may result in a clinical and hematological
responses but with persistence of the abnormal LGL clone that circulates in the blood,
supporting the proposal that cyclosporin A acts only at the functional level by inhibiting T-cell
activation.6,7 Our case also illustrates that combined staining with relevant T-cell associated and
anti-TCR-Vb MAb is a very sensitive method for assessing the therapeutic effect and evaluating
the residual disease at levels that were undetectable by molecular analysis of TCR-beta chain
gene using conventional Southern blotting. The value of Southern blot for determining T-cell
clonality is considerably limited when the clonal T-cell population represent a minor proportion
of the total nucleated cells (e.g. less than 10%) in the sample.
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